PFO
SABS icon

Pathstone Family Office’s SAB Biotherapeutics SABS Stock Holding History

Pathstone Family Office’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$319K Buy
+50,651
New +$372K ﹤0.01% 1277

Other funds holding SABS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pathstone Family Office's SABS Position: Q3 2023 in Review

Pathstone Family Office opened a new position in SAB Biotherapeutics (SABS) in Q3 2023: 50,651 shares worth $319K. The stake represents ﹤0.01% of the portfolio and ranks #1277 among its holdings.

34 funds tracked by Wall St. Rank hold SABS as of Q3 2023.

  • Pathstone Family Office held 50,651 shares of SAB Biotherapeutics worth $319K as of Q3 2023.
  • SAB Biotherapeutics was a new Pathstone Family Office position in Q3 2023.
  • SAB Biotherapeutics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1277 holding.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.